DXM infants had higher MOSs than high-dose DXM infants (β = -0.535; 95% CI -0.594 to -0.132; p = 0.003). Out of 17 infants, 2 died, 14 developed normally, and 1 developed with mild neurodevelopmental impairments. Infants whose GMs/ FMs remained normal or improved had better outcomes than infants whose GMs/FMs remained abnormal (p = 0.019). Conclusions: Out of the 17 infants treated with low-dose DXM, 2 died. Of the surviving infants, neurological functioning improved with the majority having normal neurodevelopment at the age of 12-36 months.
A valuable tool to investigate the neurological condition of young infants is to assess the quality of their general movements (GMs) [6] . Chronologically, two types of GMs can be distinguished. Up to term age, GMs are normally characterized by variability, complexity, and fluency. At 6-9 weeks after term, fidgety GMs (FMs) emerge and remain present until 15-20 weeks after term. These are defined as continuous small, circular movements of moderate speed in all directions. A persistent pattern of cramped-synchronized GMs [7] and the absence of FMs [8] specifically predict cerebral palsy (CP). Previously, it was reported that high-dose DXM leads to deterioration in the quality of GMs and FMs, which in turn relates to worse neurological outcomes at 2 years [9, 10] . It is unknown whether low-dose DXM treatment affects GM quality similarly.
Our first aim was to assess GM/FM quality in infants after low-dose DXM treatment up to 3 months postterm. Our second aim was to determine whether DXM-related risk factors were associated with GM/FM quality. We expected around 45% of infants with BPD to develop minor neuromotor disabilities, independent of BPD grading. In infants with mild or moderate BPD, we expected around 20% to develop major neuromotor disabilities with percentages increasing to 45% in infants with severe BPD [11] .
Methods

Participants
We selected preterm infants (<32 weeks' GA) admitted to our NICU between 2010 and 2012, and treated with low-dose DXM. Treatment indications were ventilator dependency with ventilatory mean airway pressure >12 cm H 2 O and/or fractional inspirational oxygen requirement >0.50 after the 10th postnatal day in infants in whom weaning stagnated despite optimal supportive therapy. DXM treatment was administered in a tapering course of either 6 days (total 1.125 mg/kg) or 15 days (total 2.025 mg/ kg). As part of clinical care, we evaluated the infants' clinical neurological status by assessing their GM/FM quality. The study was approved by the institutional review board. Prior to making the recordings, we obtained the informed consent of the parents.
Data Collection
We classified BPD into mild, moderate, or severe according to the NICHD criteria [12] . Follow-up consisted of a neurological examination according to Touwen [13] . We used the most recent follow-up data for classifying children as normal, i.e. no signs of minor neurological dysfunction (MND) and no signs of CP, mildly abnormal, i.e. signs of MND, or abnormal, i.e. signs of CP. Follow-up data were available at the corrected ages of 12 (n = 5), 18 (n = 4), 24 (n = 5) and 36 (n = 1) months.
Video Recording
Infants were recorded before treatment commenced (day 0; individual reference), on days 1, 2, and 7 following treatment, around term age, and at 3 months postterm. Few recordings were missing due to logistic problems (n = 3 before DXM treatment; n = 4 at day 1; n = 1 at day 2; n = 2 at day 7; n = 1 at term age), drop-out (n = 2 at term age; n = 2 at 3 months), or sleepy state (n = 1 at term age). We had recordings until term age of 1 patient who died. Of the other patient who died, we had recordings until 1 week after treatment commenced. Altogether 82 recordings were used for further analyses.
Analysis of GMs and FMs
The recordings were assessed off-line by MMH and AMR according to Prechtl's method [6] , and blinded for outcome. First, we classified the quality of the GMs and FMs as normal or abnormal. For the recordings up to term age, we performed a more detailed analysis by calculating a motor optimality score (MOS) using the GM Optimality List [14] . Eight different aspects, including GM quality, are distinguished. MOSs range from 8 to 18; low to high optimality. For the assessment of the MOS around 3 months of age, we used the Motor Optimality List for Fidgety Movements [15] . Five aspects, including FM quality, are distinguished. During this period, MOSs range from 5 to 28; low to high optimality. In case of doubt, the infants' recordings were re-evaluated with AFB to pass the definitive judgment. The interrater agreement for the quality of GMs/FMs was excellent (n = 82 recordings; Cohen's κ 0.89). If we allowed a difference of 1 point the interrater agreement for the MOS was high (n = 57 recordings; Cohen's κ 0.66). In case of a 2-point difference, Cohen's κ increased to 0.84 (n = 57 recordings).
Statistical Analysis
We used the χ 2 test for trend to evaluate whether GM quality changed over the consecutive recordings. We determined GM trajectories by comparing GM quality before DXM to GM quality during the last recording (thus including FM quality) with McNemar's χ 2 test. To determine the change in MOSs on day 7, we used the Wilcoxon signed-rank test with each infant serving as its own control. We then used Spearman's ρ and Fisher's exact test to relate several risk factors to GM trajectory (remained normal or improved vs. remained abnormal), MOSs on day 7 and at 3 months. Finally, we used linear regression analyses to test whether MOSs at 3 months differed between infants treated with low-dose DXM and a historical cohort of infants who were treated with high-dose DXM (n = 17) or hydrocortisone (HC; n = 17) [16] . Previously, the median MOS between 11 and 17 weeks postterm was 24 with a standard deviation of 5.6 [15] . We considered a difference in MOS of 4 points relevant, resulting in a power of 84%. We adjusted for known risk factors for adverse neurological outcomes and/or variables that differed between the cohorts with p values <0.01, i.e. GA, BPD, Nursery Neurobiologic Risk Score (NBRS), brain abnormalities on ultrasound, and the postnatal day of starting treatment. In order to meet the conditions required for linear regression analyses, we transformed MOSs into a negative logarithm with the formula: log(29.6 -[MOS]). Throughout the analyses, two-sided p values <0.05 were considered statistically significant. We used SPSS 20.0 software (SPSS, Inc., Chicago, Ill., USA) for the analyses. Table 1 provides an overview of the patient characteristics. All infants commenced DXM treatment after the second postnatal week.
Results
Patient Characteristics
Quality of GMs, FMs and MOSs
The individual trajectories of GM/FM quality are presented in figure 1 . The percentages of infants with normal GM/FM quality increased significantly over time (p < 0.001). Out of 13 infants who initially showed abnormal GMs, 9 developed normal GMs/FMs ( table 2 ; p = 0.004).
MOSs on day 7 (median 12, range 9 − 17) tended to be higher than MOSs before DXM treatment ( fig. 2 ; median 10, range 9 − 18; p = 0.082).
DXM-Related Risk Factors and GM Trajectory, MOS on Day 7 and at 3 Months
Infants whose GMs/FMs remained normal or improved were on the ventilator for a shorter time and had higher birth weights than infants whose GMs/FMs remained abnormal (ρ = − 0.524; p = 0.032 and ρ = 0.499; p = 0.042, respectively). Infants who started DXM treatment later had higher MOSs on day 7 (ρ = 0.499; p = 0.047). All infants whose GMs/FMs remained abnormal had severe BPD (p = 0.103). After excluding the 2 infants that died, the duration of mechanical ventilation was no longer associated with GM trajectory (p = 0.130). Cumulative DXM dose, treatment duration, time to extubation, duration of supplemental oxygen, GA, NBRS, and brain abnormalities were not associated with GM trajectory or MOSs on day 7 or at 3 months.
Comparison of MOS Low-Dose DXM with High-Dose DXM and Hydrocortisone
Low-dose DXM infants had higher MOSs at 3 months than high-dose DXM infants ( fig. 3 ; β = -0.535; 95% CI 
Neurological Outcome at 12-36 Months' Corrected Age
Two patients died of end-stage BPD; 1 died at 10 weeks after birth (37 weeks' postmenstrual age) and the other at 20 weeks after birth (47 weeks' postmenstrual age). Of the surviving infants, 14 developed normally and 1 developed mildly abnormal ( table 2 ) . Sensitivity and specificity were 0.67 and 0.86, respectively. Positive and negative predictive values were 0.50 and 0.92, respectively. Infants whose GMs/FMs remained normal or improved developed normally more often (12 out of 13) than infants whose GMs/ FMs remained abnormal (2 out of 4; p = 0.019). 
Discussion
Our study of preterm infants, including those who initially had abnormal GMs, indicated that following low-dose DXM treatment the quality of their GMs/FMs improved. In addition, we found that a shorter period of mechanical ventilation and starting treatment later were also associated with improved GM/FM quality. Infants treated with lower DXM doses had higher MOSs than a historical cohort of infants treated with higher doses.
The GM trajectories of low-dose DXM infants followed a similar course like the GM trajectories of untreated preterm infants in a previous cohort, with most infants' GMs normalizing after the first week of life [14] . We also found that infants who were started on DXM at later postnatal ages had higher MOSs on day 7 after treatment commenced. Perhaps the potentially adverse effects of DXM on the developing brain are mitigated if administered at a later age, when the cerebrovascular system is less vulnerable. This finding agrees with De Vries and Bos [17] who observed that younger infants displayed abnormal GMs more often than older infants.
Our mortality rate (11.7%) was comparable to the 12.5 and 11.4% previously reported in infants treated with starting DXM doses <0.5 mg/kg/day [2, 4] . Of the surviving infants, only 1 developed MND (6%), while the remainder showed no neurological abnormalities at followup, outcomes being more favorable than reported in a similar study including infants treated with high-dose DXM [10] . In that study, 39% of infants developed CP, 39% developed MND, and 22% developed normally at the age of 1-2 years. The two study groups were comparable with regard to birth weight and GA, although treatment commenced earlier (median day 15) in the cohort of Bos et al. [10] .
Although conclusive data on neurodevelopment are lacking [2] [3] [4] [5] [18] [19] [20] , low-dose DXM treatment seems to be as effective as high-dose DXM treatment in weaning infants off the ventilator, lowering BPD rates, and in decreasing the total duration of supplemental oxygen [2, 21] . The rate of BPD in our study, however, was high (94%) compared to previous studies on low-dose DXM, e.g. BPD rates vary from 52 to 85.7% [2, 22, 23] . Possibly the prevalence of BPD in our cohort was high because we started treatment in case the infants required rather high levels of respiratory support. Despite the high prevalence of BPD, we were able to extubate 59% of the infants within 10 days, which was comparable to the 60% extubation success rate in infants treated with DXM at starting doses of 0.15 mg/kg [22] . Furthermore, apart from the 2 infants who died of severe BPD, the remaining infants with either mild or moderate BPD all developed normally which is highly exceeding the 30% reported previously [11] .
Infants whose GMs/FMs remained abnormal were ventilated mechanically for a longer period than infants whose GMs/FMs remained normal or improved. This observation replicates findings by others who demonstrated that artificial ventilation was associated with deteriorating GMs or FMs [14, 24] . An explanation for the deterioration of GMs/FMs in infants with prolonged mechanical ventilation might be the disruption of the integrity of cerebral white matter [25] .
Low-dose DXM-treated infants had significantly higher MOSs at 3 months than high-dose DXM-treated infants. Within the cohort of low-dose DXM infants, cumulative doses were not associated with GM trajectories or MOSs on day 7 or at 3 months. Starting doses of DXM might have a greater effect on the integrity of the central nervous system than the cumulative doses of DXM. This hypothesis is supported by 2 randomized trials that reported comparable neurodevelopmental outcomes at 18 months between infants treated with similar starting doses (0.5 mg/kg/day) but different cumulative DXM doses [21, 26] .
The strength of our study was its longitudinal design. By assessing GM/FM quality before and after DXM treatment, we could directly observe the effect of low-dose DXM on neurological functioning.
Our study also had some limitations. First, the number of infants included was small and thus the results should be interpreted with caution. For example, to demonstrate differences in CP rates of 2% between infants treated with low-dose DXM compared to either HC-treated or untreated infants, we should have included over a thousand participants. Second, by not including a control group, we were unable to directly compare the GM/FM quality of low-dose DXM infants with untreated infants. In our cohort each infant served as its own control, and the normalization of GMs has proven to be a reliable predictor of neurological functioning [17] . This was confirmed in our cohort. Third, we compared MOSs of low-dose DXMtreated infants with a historical cohort of infants treated with high-dose DXM or HC. Since the former were recruited between 2010 and 2012 and the latter between 1992 and 2006, the higher MOSs in low-dose DXM infants might also be attributable to overall improvements in neonatal care. Fourth, the duration of the follow-up was insufficient to draw definitive conclusions regarding long-term neurological functioning. Finally, outcome as reported in this study was limited to neurological functioning, so we might have missed cognitive or behavioral problems. Even so, mild abnormalities may only become evident at later ages.
Conclusion
In preterm infants at risk of BPD and treated with DXM at a starting dose of 0.25 mg/kg/day after the second postnatal week, neurological functioning improved over time. Neurodevelopment at the age of 12-36 months was normal in the majority of surviving infants. Nevertheless, randomized controlled trials of low-dose DXM and HC without an open-label use of corticosteroids are urgently needed to investigate long-term respiratory and neurological outcomes.
